

07 July 2026

## Botanix announces European Patent Office Intention to Grant a patent covering proprietary applicator technology

**Phoenix AZ, 07 July 2026:** Commercial dermatology company, Botanix Pharmaceuticals Limited (ABN 70 009 109 755) (ASX:BOT, “Botanix” or “the Company”), announces that the European Patent Office (“EPO”) has issued an Intention to Grant, for European patent application, EP 19799730.7, ‘Applicator and System for Pharmaceutical Preparation and Method of Use’, which covers proprietary applicator technology used with sofpironium topical gel, 12.45%, the drug product branded as *Sofdra*® in the US.

The patent application covers commercially relevant aspects of the applicator device utilised with the Company’s topical gel product, including features designed to support controlled topical administration and patient use. Following completion of the formal grant process and validation in selected European countries, the patent is expected to provide protection into May 2039.

*‘We are pleased to receive this positive decision from the EPO, which further strengthens Botanix’s intellectual property estate surrounding the delivery and administration of sofpironium topical gel,’ said Dr Howie McKibbin, Chief Executive Officer of Botanix. ‘The applicator technology is an important part of the overall Sofdra product profile and physicians have told us that the applicator, which helps limit unwanted drug contact to the hands, is one of the key reasons they prescribe Sofdra.’*

This Intent to Grant is expected to enhance the Botanix value proposition for potential ex-US commercialisation pathways in Europe, where *Sofdra* is not currently available.

Release authorised by

**Vince Ippolito**

Executive Chairman

### About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a dermatology company based in Philadelphia and Phoenix (US), which has received FDA approval for *Sofdra*, its product for the treatment of primary axillary hyperhidrosis. *Sofdra* is the first and only new chemical entity approved by FDA to treat primary axillary hyperhidrosis and presents a novel, safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

To learn more, please visit: <http://www.botanixpharma.com/>

### For more information, please contact:

General enquiries  
Botanix Pharmaceuticals  
Corporate Communications  
P: [+61 8 6285 0083](tel:+61862850083)  
[info@botanixpharma.com](mailto:info@botanixpharma.com)

Investor and Media Relations  
Jane Morgan Management  
Wilamina Russo  
P: [+61 450 646 609](tel:+61450646609)  
[wr@janemorganmanagement.com.au](mailto:wr@janemorganmanagement.com.au)

For personal use only

### Cautionary Note on Forward-Looking Statements

Forward-looking statements can generally be identified by the use of forward-looking words such as, “expect”, “anticipate”, “likely”, “intend”, “should”, “could”, “may”, “predict”, “plan”, “propose”, “will”, “believe”, “forecast”, “estimate”, “target”, “outlook”, “guidance” and other similar expressions and include, but are not limited to, plans and prospects for the Company, the Company’s strategy, future operations, the expected timing and/or results of regulatory approvals and prospects of commercialising product candidates or research collaborations with its partners, including in Japan, the outcome and effects of *Sofdra* and the market for *Sofdra*. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements. The forward-looking statements contained in this Presentation are not indications, guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of Botanix, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. Investors should consider the forward-looking statements contained in this Presentation in light of those disclosures and not place undue reliance on such statements. Except as required by law or regulation, Botanix undertakes no obligation to update forward-looking statements.